Evofem Biosciences, Inc. provided sales guidance for the fiscal year 2022. For the year, the company expects net product sales will be in the range of $30 million to $35 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0119 USD | -4.96% | -15.60% | -81.41% |
May. 16 | Transcript : Evofem Biosciences, Inc. - Special Call | |
May. 15 | Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-81.41% | 933K | |
+45.95% | 754B | |
+40.95% | 630B | |
-5.86% | 352B | |
+19.90% | 331B | |
+9.55% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+5.92% | 164B |
- Stock Market
- Equities
- EVFM Stock
- News Evofem Biosciences, Inc.
- Evofem Biosciences, Inc. Provides Sales Guidance for the Fiscal Year 2022